Loading
Every dated change on the records linked to Merkel cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Objective response in 54.
Objective response 54.5 per cent in 101 chemotherapy-naive patients, median progression-free survival 16.0 months and 63 per cent alive at three years.
Metastatic or recurrent locally advanced Merkel cell carcinoma
ADMEC-O randomised 179 patients with completely resected Merkel cell carcinoma 2 to 1 to a year of nivolumab or to observation. Disease-free survival was 85 per cent at 12 months and 84 per cent at 24 with nivolumab against 77 and 73 per cent with observation, a hazard ratio of 0.58 whose 95 per cent confidence interval, 0.30 to 1.12, crosses one; the authors state it as an absolute risk reduction of 9 and 10 percentage points. Grade 3 or 4 adverse events occurred in 42 per cent against 11 per cent. Overall survival had ten events against six in a group half the size and is not mature. This is a phase 2 signal in a rare disease, not a proven standard, and the randomised phase 3 that would settle it, STAMP, has not reported.
Disease-free survival 85 per cent at 12 months and 84 per cent at 24 months with adjuvant nivolumab against 77 and 73 per cent with observation (hazard ratio 0.
179 patients randomised 2 to 1 to a year of nivolumab or observation; disease-free survival 84 against 73 per cent at 24 months, hazard ratio 0.58 with a confidence interval crossing one, and overall survival not mature.
A milestone in how this cancer is treated.
Objective response 31.
Objective response 56%, durable in most responders; similar in virus-positive and virus-negative tumours.
A milestone in how this cancer is treated.